TELA Bio Reports First Quarter 2026 Financial Results

TELA Bio, Inc. announced its financial results for the first quarter of 2026, reporting revenues of $19.1 million, a 3% increase from the previous year. The company’s gross profit was $12.5 million, reflecting a gross margin decrease due to inventory write-offs. Operating expenses remained stable at $23 million, with a net loss of $12.3 million, wider than the previous year’s loss. TELA Bio has launched OviTex LTR in the U.S. and is expanding its presence in Europe. The company maintains its financial guidance for 2026.